论文部分内容阅读
目的:探讨阿帕替尼联合依托泊苷治疗铂耐药复发性卵巢癌患者的疗效及安全性。方法:回顾性分析吉林省肿瘤医院2017年1月至2018年6月诊治的铂耐药复发性卵巢癌63例患者的临床及随访资料，根据治疗方式的不同将患者分为单药组(n n＝28)和联合组(n n＝35)，单药组患者接受口服依托泊苷胶囊治疗，联合组患者接受阿口服帕替尼联合依托泊苷胶囊治疗。比较两组患者的近期临床疗效、无进展生存时间(PFS)及不良反应。n 结果:两组患者主要的不良反应为贫血及白细胞降低，两组患者各种不良反应发生情况比较，差异均无统计学意义(均n P>0.05)。联合组客观有效率(ORR)为54.3%(19/35)，高于单药组的25.0%(7/28)，差异有统计学意义(χn 2＝5.504，n P<0.05)。联合组患者的PFS为8个月(95%n CI：7.4～8.6个月)，明显长于单药组的4个月(95%n CI：3.5～4.5个月)，差异有统计学意义(χn 2＝52.400，n P0.05). The objective response rate(ORR) of the combined group was 54.3%(19/35), which was higher than that of the single group [25.0%(7/28)](χn 2=5.504, n P<0.05). The PFS of the combined group was 8 months(95%n CI: 7.4-8.6 months), which was significantly longer than that of the single group(4 months, 95%n CI: 3.5-4.5 months), the difference was statistically significant(χn 2=52.400, n P<0.01).n Conclusion:Apatinib combined with etoposide capsules is effective in the treatment of platinum resistant recurrent ovarian cancer, which can significantly extend the median PFS, without increasing the incidence of serious adverse reactions.